Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with ...

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain ...

Black patients with metastatic triple-negative breast cancer received immunotherapy less frequently than patients of other ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was ...

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

Bristol Myers (BMY) announced that the U.S. Food and Drug Administration approved Opdivo plus Yervo as a first-line treatment of adult and ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...